Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Interest Expenses (2018 - 2025)

Historic Interest Expenses for Serina Therapeutics (SER) over the last 7 years, with Q3 2025 value amounting to $6000.0.

  • Serina Therapeutics' Interest Expenses fell 6250.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $32000.0, marking a year-over-year decrease of 9532.85%. This contributed to the annual value of $526000.0 for FY2024, which is 573.48% down from last year.
  • Latest data reveals that Serina Therapeutics reported Interest Expenses of $6000.0 as of Q3 2025, which was down 6250.0% from $9000.0 recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' Interest Expenses peaked at $978000.0 during Q4 2022, and registered a low of $6000.0 during Q3 2025.
  • For the 5-year period, Serina Therapeutics' Interest Expenses averaged around $307875.0, with its median value being $181000.0 (2023).
  • In the last 5 years, Serina Therapeutics' Interest Expenses soared by 23152.54% in 2022 and then crashed by 9706.84% in 2025.
  • Quarter analysis of 5 years shows Serina Therapeutics' Interest Expenses stood at $295000.0 in 2021, then surged by 231.53% to $978000.0 in 2022, then plummeted by 82.0% to $176000.0 in 2023, then tumbled by 90.34% to $17000.0 in 2024, then plummeted by 64.71% to $6000.0 in 2025.
  • Its Interest Expenses stands at $6000.0 for Q3 2025, versus $9000.0 for Q2 2025 and $17000.0 for Q4 2024.